Thepathogenesis of sepsis: Current aspects


如何引用文章

全文:

作者简介

S Grachev

ММА им. И. М. Сеченова

ММА им. И. М. Сеченова

S Pak

ММА им. И. М. Сеченова

ММА им. И. М. Сеченова

V Malov

ММА им. И. М. Сеченова

ММА им. И. М. Сеченова

Ye Gorodnova

ММА им. И. М. Сеченова

ММА им. И. М. Сеченова

参考

  1. Slutsky A., Whitehead Т., Zhang H. Clinical Trials Update: Future Direction for. In: Program and abstracts of the Fifth Toronto critical care medicine symposium. 2000. 34-38.
  2. Marshall J. С Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit. Care Med. 2001; 29 (7): 99-106.
  3. Bone R. С The pathogenesis of sepsis. Ann. Intern. Med. 1991; 115:457-469.
  4. Grinnell B. W., Joyce D. Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis. Crit. Care Med. 2001; 29 (7): 53-61.
  5. Sepsis: A significant Healthcare Challenge, www.sepsis.com <http://www.sepsis.com>.
  6. Малое В. А., Пак С. Г. Эволюция взгляда на роль бактериальных липополисахаридов в патологии человека. Вестн. РАМН 1997; 8: 33-38.
  7. Белобородое В. Б. Сепсис - современная проблема клинической медицины. Рус. мед. журн. 1997; 5 (24): 326-338.
  8. Coughlin S. R. Sol Sherry lecture in thrombosis: How thrombin "talks" to cells: Molecular mechanisms and roles in vivo. Arterioscler. Thromb. Vase. Biol. 1998; 18: 514-518.
  9. Gogos С A., Drosou E., Bassaris H. P. et al. Pro-versus antiinflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. Infect. Dis. 2000; 181: 176-180.
  10. Volk D., Reinke P., Docke W. D. Immunostimulation with cytokines in patients with immunoparalysis. In: Marshall J. C,Cohen J. Immune response in the critically ill. Berlin: Spring r-Verlag; 1999. 393-404.
  11. Levi M., Van der Poll Т., ten Cate H. et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur. J. Clin. Invest. 1997; 27: 3-9.
  12. Esmon С. Т. Protein С anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit. Care Med. 2001; 29 (7): 48-52.
  13. Danner R. L., Elin R. J., Hosseini J. M. et al. Endotoxemia in human septic shock. Chest. 1991; 99: 169-175.
  14. Wheeler A. P., Bernard G. R. Treating patients with severe sepsis. N. Engl. J. Med. 1999; 340: 207-214.
  15. Carvalho A. C, Freeman N. J. How coagulation defects alter outcome in sepsis: Survival may depend on reversing procoag ulant conditions. J. Crit. Ulnes. 1994; 9: 51-75.
  16. Cohen J. Plenary session: sepsis in the critically ill: back to the future. In: Program and abstracts of the 30"' International educational and scientific symposium of the Society of critical care medicine. San Francisco, California; 2001. 44-48.
  17. Kidokoro A., Iba Т., Fukunaga M. et al. Alteration in coagulation and fibrinolysis during sepsis. Shock 1996; 5: 223-228.
  18. Martin G. S. Diagnosis and treatment of the critically ill sepsis patient. In: 30"' International educational and scientific symposium of the Society of critical care medicine. San Francisco, California; 2001. 122-126.
  19. Natanson C, Esposito С J., Banks S. M. The siren's songs of confirmatory sepsis trials: selection bias and sampling error. Crit. Care Med. 1998; 26: 1927-1931.
  20. Zeni F., Freeman В., Natanson S. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Ibid. 1997; 25: 1095-1100.
  21. Levi M., ten Gate H. Disseminated intravascular coagulation.N. Engl. J. Med. 1999; 34: 86-92.
  22. www.soros.karelia.ru <http://www.soros.karelia.ru>
  23. De Jonge E., Dekkers P. £., Creasey L. et al. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.
  24. Ten Gate J. W., Van der Poll Т., Levi M. et al. Cytokines: Triggers of clinical thrombotic disease. Thromb. and Haemost. 1997;78:415-419.
  25. Lorant D. E., Topham M. K., Whatley R. E. et al. Inflammato ry roles of P-selectin. J. Clin. Invest. 1993; 92: 559-570.
  26. Levi M., de Jonge E., van der Poll T. Rational for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit. Care Med. 2001; 29: 90-94.
  27. Levi M., de Jonge E., van der Poll T. Novel approaches to the management of disseminated intravascular coagulation. Crit. Care Med. 2000; 28: 20-24.
  28. Buller H. R., ten Gate J. W. Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am. J. Med. 1989; 87: 44-48.
  29. Blauhut В., Kramar H., Vinazzer H. et al. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb. Res. 1985; 39:81-89.
  30. Esmon C. T. The protein С Pathway. Crit. Care Med. 2000; 28: 44-48.
  31. Esmon С. Т. Inflammation and thrombosis: Mutual regulation by protein С Immunologist 1998; 6: 84-89.
  32. Grinnell B. W., Yan S. B. Novel antithrombotics based on modulation of the protein С pathway. Coron Artery Dis. 1998; 9: 89-97.
  33. Nawroth P. P., Stern D. M. Modulation of endothelial cell haemostatic properties by tumor necrosis factor. J. Exp. Med. 1986; 163: 740-745.
  34. Esmon С. Т. The endothelial cell protein С receptor. Thromb. and Haemost. 2000; 83: 639-643.
  35. Esmon C. T. Molecular events that control the protein С anticoagulant pathway. Ibid. 1993; 70: 29-35.
  36. Esmon С. Т., Fukudome K., Mather T. et al. Inflammation, sepsis, and coagulation. Haematologica 1999; 84: 254-259.
  37. Fisher С J., Yan S. B. Protein С levels as a prognostic indica- tor of outcome in sepsis and related diseases. Crit. Care Med. 2000; 28: 49-56.
  38. Garcia de Frutos P., Alim R. /., Hardig Y. et al. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84: 815-822.
  39. Yan S. В., Grinnell B. W. Recombinant human protein C, protein S and thrombomodulin as antithrombotics. Perspect. Drug Discovery Design 1994; 1: 504-520.
  40. Yan S. В., Grinnell B. W. Anti-thrombotic and anti-inflammatory agents of the protein С anticoagulant pathway. Ann. Rep. Med. Chem. 1994; 11: 103-112.
  41. Mann K. G, van't Veer C, Cawthern K. et al. The role of tissue factor pathway in initiation of coagulation. Blood Coagul. Fibnnolys. 1998; 9 (suppl. 1): 3-7.
  42. Shimura M., Wada H., Wakita Y. et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am. J. Haematol. 1997; 45. 55: 169-174.
  43. Bakker H. M., Tans G, Janssen-Claessen T. et al. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C.Eur. J. Biochem. 1992; 208: 171-178.
  44. Vervloet M., Thijs L., Hack C. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin. Thromb. Haemost. 1998; 24: 33-44.
  45. Bernard G. R., Hartman D. L., Helterbrand J. D. et a Recom-binant human activated protein С (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients in severe sepsis. Crit. Care Med. 1999; 27: 4.
  46. Wesley E. F., Jr., Esmon С. Т., Fisher С. J. Jr. et al. New evolutions in understanding and managing patients with sepsis. Crit. Care Treatm. Updates 2000; 42-53.

版权所有 © Consilium Medicum, 2003

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 
 


##common.cookie##